Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu

被引:80
作者
Montagna, C
Andrechek, ER
Padilla-Nash, H
Muller, WJ
Ried, T
机构
[1] NCI, Ctr Canc Res, Genet Branch, NIH, Bethesda, MD 20892 USA
[2] McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, Hamilton, ON L8S 4K1, Canada
关键词
HER2/neu; spectral karyotyping (SKY); breast cancer model; genomic instability; double minutes (DMs); centrosome;
D O I
10.1038/sj.onc.1205146
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The conditional expression of activated HER2/neu gene under its endogenous promoter in the mammary epithelium of the mouse results in accelerated lobular development and focal mammary tumors. Carcinogenesis, however, requires amplification and considerably increased expression levels of oncogenic neu. Deducing from the multiple genetic aberrations required for human breast cancer to develop, we hypothesized that in addition to the over-expression of an activated HER2/neu, secondary aberrations would occur. We have therefore conducted a genomic screen for chromosomal imbalances and translocations using comparative genomic hybridization and spectral karyotyping. The results reveal a moderate degree of chromosomal instability and micronuclei formation in short-term cultures established from primary tumors. Genomic instability appears to be linked to the amplification of functional centrosomes, a phenomenon that we frequently observed in other tumor types. Seventy per cent of the tumors revealed genomic amplification of HER2/neu, often in the form of double minute chromosomes, which correlated with recurring loss of mouse chromosome 4D-E, a region that is orthologous to distal human chromosome 1p. It is likely that this region contains putative tumor suppressor genes whose inactivation is required for tumor formation in this model of human breast cancer.
引用
收藏
页码:890 / 898
页数:9
相关论文
共 39 条
[11]  
Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.3.CO
[12]  
2-G
[13]  
Heim S., 2015, CANC CYTOGENETICS
[14]   Mouse models for breast cancer [J].
Hennighausen, L .
ONCOGENE, 2000, 19 (08) :966-967
[15]  
ISOLA JJ, 1995, AM J PATHOL, V147, P905
[16]   COMPARATIVE GENOMIC HYBRIDIZATION FOR MOLECULAR CYTOGENETIC ANALYSIS OF SOLID TUMORS [J].
KALLIONIEMI, A ;
KALLIONIEMI, OP ;
SUDAR, D ;
RUTOVITZ, D ;
GRAY, JW ;
WALDMAN, F ;
PINKEL, D .
SCIENCE, 1992, 258 (5083) :818-821
[17]  
KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.biochem.63.1.639
[18]   Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice [J].
Liu, ML ;
Von Lintig, FC ;
Liyanage, M ;
Shibata, MA ;
Jorcyk, CL ;
Ried, T ;
Boss, GR ;
Green, JE .
ONCOGENE, 1998, 17 (18) :2403-2411
[19]   Multicolour spectral karyotyping of mouse chromosomes [J].
Liyanage, M ;
Coleman, A ;
duManoir, S ;
Veldman, T ;
McCormack, S ;
Dickson, RB ;
Barlow, C ;
WynshawBoris, A ;
Janz, S ;
Wienberg, J ;
FergusonSmith, MA ;
Schrock, E ;
Ried, T .
NATURE GENETICS, 1996, 14 (03) :312-315
[20]   Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability [J].
McCormack, SJ ;
Weaver, Z ;
Deming, S ;
Natarajan, G ;
Torri, J ;
Johnson, MD ;
Liyanage, M ;
Ried, T ;
Dickson, RB .
ONCOGENE, 1998, 16 (21) :2755-2766